explore -WSS

explore

author：knowledge 2025-10-01 02:13:57 - browse：63982

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： 2023 Nobel Prize in Medicine goes to Karikó and Weissman

leisure time

WSS

European regulators consider appeal over Amylyx ALS drug

Medicare innovation center doesn’t save money, experts say

The biotech scorecard for Q4: 16 stock

STAT Readout: Today's biotech news includes Sana and Amylyx

Health insurers' Q3 question: how much care are people getting?

STAT Readout Newsletter: Today in biotech, life science news

focus

explore

Lobbying power of AI, software-enabled devices

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

What will Novo Nordisk's VC do with its influx of cash?

Activists slam private health insurers over coverage restrictions

IVG is promising — but it won’t replace IVF quite yet

Tori Bowie and the unacceptable rates of Black maternal death

With Roe v Wade overturned, abortion providers work to adapt

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Peter Hotez and the public health issue of online harassment

Nobel honors Karikó and Weissman's enduring partnership

leisure time

Female surgeons have lower rates of long

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Will an HIV vaccine ever be a reality?

RSV injection headlines need to be accurate for good uptake

New oral drug delivery patch is modeled after octopus tentacles

What's changing in Medicare's open enrollment this year?

hotspot

leisure time

leisure time

hotspot